TrapEase Inferior Vena Cava Filter
The TrapEase Permanent Vena Cava Filter is an inferior vena cava filter (IVC filter) manufactured by Cordis Endovascular and Johnson & Johnson. IVC filters are designed to be placed in the vena cava of the heart with the intention of preventing pulmonary embolisms.
The TrapEase filter is designed for use in patients who have suffered from conditions such as heart attacks, stroke and deep vein thrombosis but can’t be given normal anticoagulant medication to prevent further blood clots. However, studies have found that IVC filters including the TrapEase filter may not be effective and also increase the risks of serious side effects.
The TrapEase IVC filter has been found to have a higher risk of blood clots compared to alternative treatments. These blood clots could lead to deep vein thrombosis (DVT) and other serious conditions, such as stroke or heart attack.
The TrapEase filter has also been found to fracture at a higher rate than normal, which can lead to serious complications and a need for immediate surgery to remove the device. In a Japanese trial, as many as half of the patients suffered device fracture within 50 months of receiving the TrapEase IVC.
Johnson & Johnson allegedly knew about the complications associated with TrapEase as early as 2011, but failed to warn doctors or patients. Patients who have suffered TrapEase blood clots and fractures have begun filing lawsuits against Johnson & Johnson alleging the company released a defective device.
If you were implanted with a defective TrapEase IVC filter and experienced device fracture or deep vein thrombosis, contact the lawyers at Hissey Kientz, LLP to learn more about your legal rights. You can reach us by calling toll free at 1-866-275-4454, or by filling out a free case evaluation form on the right of this page.